Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.91 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP4 | P49662 | 2/20 | 0.40 |
| ▸ | CASP5 | P51878 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809044 | 0.95 | PPARG (1.00) | PPARGPPARAPPARDCASP1CASP4 | |
| SCHEMBL2805810 | 0.95 | PPARG (1.00) | PPARGPPARAPPARDCASP1CASP4 | |
| SCHEMBL2812228 | 0.95 | PPARG (1.00) | PPARGPPARAPPARDCASP1CASP4 | |
| SCHEMBL2807152 | 0.93 | PPARG (0.92) | PPARGPPARAPPARDCASP1CASP4 | |
| SCHEMBL2804992 | 0.92 | PPARG (0.88) | PPARGPPARAPPARDCASP1CASP4 | |
| SCHEMBL2804677 | 0.92 | PPARG (0.91) | PPARGPPARAPPARDCASP1CASP4 | |
| SCHEMBL2804633 | 0.92 | PPARG (0.91) | PPARGPPARAPPARDCASP1CASP4 | |
| SCHEMBL2804704 | 0.92 | PPARG (1.00) | PPARGPPARAPPARDFAAH | |
| SCHEMBL2810986 | 0.92 | PPARG (0.87) | PPARGPPARACASP1CASP4CASP5 | |
| SCHEMBL2806780 | 0.91 | PPARG (0.92) | PPARGPPARACASP1CASP4CASP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| WO-2009046606-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.